Evidence map›Paper›PMID 35389220›Full record

ArticleACS synthetic biology2022

Bioinformatic Design of Dendritic Cell-Specific Synthetic Promoters.

Abayomi O Johnson, Susan B Fowler, Carl I Webster, Adam J Brown, David C James

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS synthetic biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Abayomi O JohnsonDepartment of Chemical and Biological Engineering, University of Sheffield, Mappin Street, Sheffield S1 3JD, U.K.ORCID 0000-0002-3519-4269
Susan B FowlerAntibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge CB21 6GH, U.K.
Carl I WebsterDiscovery Sciences, R&D, AstraZeneca, Cambridge CB21 6GH, U.K.
Adam J BrownDepartment of Chemical and Biological Engineering, University of Sheffield, Mappin Street, Sheffield S1 3JD, U.K.
David C JamesDepartment of Chemical and Biological Engineering, University of Sheffield, Mappin Street, Sheffield S1 3JD, U.K.
Synopsys (Switzerland) · CHAstraZeneca (Australia) · AUAstraZeneca (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation DNA vectors for cancer immunotherapies and vaccine development require promoters eliciting predefined transcriptional activities specific to target cell types, such as dendritic cells (DCs), which underpin immune response. In this study, we describe the

Indexed as

Computational BiologyEndothelial CellsAnimalsDendritic CellsGene LibraryHumansMammalsPromoter Regions, GeneticTranscription FactorsTranscription Factorsdendritic cellsgenome miningpromoter architecturesynthetic promotertranscriptional factors

Identifiers

PMID35389220
PMCPMC9016764
OpenAlexW4224122484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.